Literature DB >> 15666033

Cytidine deaminase in polymyalgia rheumatica and elderly onset rheumatoid arthritis.

Sergio Paira1, Susana Roverano, Oscar Rillo, Alejandra Barrionuevo, Stella Mahieu, Néstor Millen.   

Abstract

Serum cytidine deaminase (CD) as a marker of inflammatory disease was assessed in 44 patients and 47 controls to differentiate polymyalgia rheumatica (PMR) from elderly onset rheumatoid arthritis (EORA). The patients were divided into four groups: PMR with and without synovitis and seropositive and seronegative EORA. No statistically significant differences were found when serum CD levels of seropositive EORA patients were compared with serum CD of PMR patients without synovitis, neither when serum CD levels of all PMR patients were compared with a seronegative EORA group, nor when serum CD levels of PMR patients with synovitis were compared with those with EORA. Nevertheless, statistically significant differences were detected between EORA's serum CD levels and the control group (p=0.023). This difference was 10% when comparing CD levels of PMR patients with the control group (p=0.070). We did not demonstrate that serum CD levels could be a useful tool to differentiate PMR from EORA, but these findings could nevertheless reflect the presence of an inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15666033     DOI: 10.1007/s10067-004-1058-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  11 in total

1.  Increased serum cytidine deaminase activity in gout and articular chondrocalcinosis.

Authors:  J Rovenský; M Stancíkova; K Bosmanský; M Kovalancík
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

2.  Synovial fluid interleukin-8 and neutrophil function in rheumatoid arthritis and seronegative polyarthritis.

Authors:  P R Troughton; R Platt; H Bird; E el-Manzalawi; M Bassiouni; V Wright
Journal:  Br J Rheumatol       Date:  1996-12

3.  Serum cytidine deaminase as a laboratory test for acute inflammation in rheumatoid arthritis.

Authors:  I M Chalmers; G T Thomson; P Desjardins
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

4.  Serum cytidine deaminase levels after withdrawal of non-steroidal anti-inflammatory treatment in rheumatoid arthritis.

Authors:  P W Thompson; J R Kirwan; D D Jones; H L Currey
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

5.  Cytidine deaminase--a new differential tool distinguishing elderly onset rheumatoid arthritis from polymyalgia rheumatica?

Authors:  R C Williams
Journal:  Clin Exp Rheumatol       Date:  1995 Sep-Oct       Impact factor: 4.473

6.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

7.  Musculoskeletal manifestations in polymyalgia rheumatica and temporal arteritis.

Authors:  J Narváez; J M Nolla-Solé; J A Narváez; M T Clavaguera; J Valverde-García; D Roig-Escofet
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

8.  Cytidine deaminase may be a useful marker in differentiating elderly onset rheumatoid arthritis from polymyalgia rheumatica/giant cell arteritis.

Authors:  D Kassimos; J R Kirwan; V Kyle; B Hazleman; P Dieppe
Journal:  Clin Exp Rheumatol       Date:  1995 Sep-Oct       Impact factor: 4.473

9.  Cytidine deaminase activity as a measure of acute inflammation in rheumatoid arthritis.

Authors:  P W Thompson; D D Jones; H L Currey
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

10.  Circadian rhythm of serum cytidine deaminase in patients with rheumatoid arthritis during rest and exercise.

Authors:  P W Thompson; I T James; S Wheatcroft; R Pownall; C G Barnes
Journal:  Ann Rheum Dis       Date:  1989-06       Impact factor: 19.103

View more
  2 in total

1.  Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.

Authors:  Milena Gusella; Felice Pasini; Caterina Bolzonella; Silvia Meneghetti; Carmen Barile; Antonio Bononi; Silvia Toso; Daniela Menon; Giorgio Crepaldi; Yasmina Modena; Laura Stievano; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

2.  Polymyalgia rheumatica: A case series from Colombia and analysis of Latin America.

Authors:  Carlos Enrique Toro-Gutiérrez; Carlos A Cañas; Rubén D Mantilla; Santiago Beltrán; Vivian Pastrana-Gonzalez; Milly J Vecino; Mónica Rodriguez-Jimenez; Manuel Rojas
Journal:  J Transl Autoimmun       Date:  2021-08-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.